Otsuka Pharmaceutical, including its U.S. division, reported promising results from two Phase 3 trials evaluating centanafadine's efficacy and safety in managing ADHD in children and teens.

ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.

TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.

Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.

Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.

The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.

Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).

Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.

Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.

Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .

Innovent Biologics recently announced the completion of the 48-week treatment phase after reaching the primary endpoint of the phase II clinical trial in obese Chinese subjects with 9mg of the GLP-1R/GCGR dual agonist, Mazdutide.

Recently, Eli Lilly announced the long-term therapeutic effects of its investigational IL-13 inhibitor, lebrikizumab, in patients with moderate to severe atopic dermatitis.